Rituximab in lupus and beyond: The state of the art

Lupus

Volumn 18, Issue 7, 2009, Pages 639-644

  Hughes, G R V ^a  

^a LONDON BRIDGE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CARDIOLIPIN ANTIBODY; CD20 ANTIGEN; CD27 ANTIGEN; COMPLEMENT COMPONENT C1Q ANTIBODY; COMPLEMENT COMPONENT C3; CYCLOPHOSPHAMIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; DOUBLE STRANDED DNA ANTIBODY; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 10; INTERLEUKIN 12; LEFLUNOMIDE; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NUCLEOSOME ANTIBODY; PLACEBO; PREDNISOLONE; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; WARFARIN;

ANTIPHOSPHOLIPID SYNDROME; B LYMPHOCYTE; CLINICAL TRIAL; CONFERENCE PAPER; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; NONHUMAN; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; REGULATORY T LYMPHOCYTE; REMISSION; RHEUMATOID ARTHRITIS; SINGLE DRUG DOSE; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS; UNSPECIFIED SIDE EFFECT; VASCULITIS;

ANTIBODIES, MONOCLONAL; ANTIPHOSPHOLIPID SYNDROME; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; B-LYMPHOCYTES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE DEPLETION; VASCULITIS;

EID: 65649099321     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203309105337     Document Type: Conference Paper

References (15)

1. Hughes G. Rituximab: An update. Lupus 2007; 16: 529-530.
2. Harris HE. Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab. Rheumatology 2008; 47: 224-225.
3. Albert D, Dunham J, Khan S, et al. Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythematosus. Ann Rheum Dis 2008; 67: 1724-1731.
4. Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum 2006; 54: 2970-2982.
5. Chang X, Gao JX, Jiang Q, et al. The Scurfy mutation of FoxP3 in the thymus stroma leads to defective thymopoiesis. J Exp Med 2005; 202: 1141-1151.
6. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol 2007; 178: 2579-2588.
7. Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, et al. Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study. Arthritis Res Ther 2006; 8: R83.
8. Shah S, Qiao L. Resting B cells expand a CD4+CD25+Foxp3+ Treg population via TGF-beta3. Eur J Immunol 2008; 38: 2488-2498.
9. Cambridge G, Isenberg DA, Edwards JC, et al. B cell depletion therapy in systemic lupus erythematosus: Relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008; 67: 1011-1016.
10. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: The effects of re-treatment in initial nonresponders versus initial responders. Arthritis Rheum 2008; 58: 3657-3664.
11. Owczarczyk K, Hellmann M, Fliedner G, et al. Clinical outcome and B cell depletion in patients with rheumatoid arthritis receiving rituximab monotherapy in comparison with patients receiving concomitant methotrexate. Ann Rheum Dis 2008; 67: 1648-1649.
12. Ruiz-Irastorza G, Khamashta MA, Hunt BJ, Escudero A, Cuadrado MJ, Hughes GR. Bleeding and recurrent thrombosis in definite antiphospholipid syndrome: Analysis of a series of 66 patients treated with oral anticoagulation to a target international normalized ratio of 3.5. Arch Intern Med 2002; 162: 1164-1169.
13. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
14. Adamson R, Sangle S, Kaul A, Hughes GR, D'Cruz DP. Clinical improvement in antiphospholipid syndrome after rituximab therapy. J Clin Rheumatol 2008; 14: 359-360.
15. Isaksen K, Jonsson R, Omdal R. Anti-CD20 treatment in primary Sjögren's syndrome. Scand J Immunol 2008; 68: 554-564.